Visudyne (Verteporfin for injection) QLT Phototherapeutics/Novartis

Regulators indicated that an additional trial would be needed to assess the efficacy of reproxalap to treat patients with dry eye. Aldeyra has submitted to the FDA a Special Protocol Assessment for the new trial.

Byooviz was approved as the first biosimilar to Lucentis and launched with a list price of $1,130 per single-use vial.

Ryzumi is expected to be available in the first half of 2024. Pricing will be available around the time of launch.

Iyuzeh can be stored at room temperature. It has a list price of $299 for a month’s supply.

Miebo, approved in May, addresses tear evaporation in dry eye disease. It will have a wholesale acquisition cost of $771 for a one-month supply.

The anti-cancer drug bevacizumab is used off-label to treat wet AMD. Outlook Therapeutics had developed an ophthalmic formulation of bevacizumab for intravitreal injection.